Sun Pharma secures ex-US, ex-China rights to cholesterol drug lerodalcibep
Sun Pharma has signed a global licensing agreement with LIB Therapeutics to commercialise and manufacture lerodalcibep outside the US and China, entering the estimated $3.7 billion PCSK9 inhibitor market.
The development
Sun Pharma signed a global licensing deal for exclusive rights outside the US and China to commercialise and manufacture Lerodalcibep in the $3.7 billion PCSK9 inhibitor market.
The numbers
- $3.7 billion
- 38 per cent
- two years to June 2026
- $2.9 billion
- September 21
- 300 mg
- 25 degrees Celsius
- six months
- 33 per cent
Why it matters to operators and investors
This transaction advances Sun Pharma’s strategy of using targeted licensing to acquire differentiated international assets and deepen its specialty-care pipeline.
What to watch next
- Regulatory submission, approval, or label-expansion announcements for lerodalcibep outside the US and China.
- Phase 3 efficacy, safety, durability, and cardiovascular-outcomes data updates.
- Upfront payment, milestone, royalty, manufacturing-transfer, or minimum-purchase terms disclosed by Sun Pharma or LIB Therapeutics.
- Reimbursement decisions and formulary access in major ex-US markets.
- Competitive pricing, biosimilar entry, and new outcome data for PCSK9 antibodies and inclisiran.
- Sun Pharma specialty-sales hiring, cardiovascular commercial partnerships, or manufacturing investments.
- Prioritize regulatory filing strategy and market sequencing across Europe, Japan, Canada, Australia, and selected emerging markets.
- Build medical-affairs evidence around LDL-C reduction, dosing convenience, cardiovascular-risk populations, and comparative value versus Repatha, Praluent, and inclisiran.
- Negotiate country-specific reimbursement, tender, and distribution agreements before broad launch commitments.
- Assess local manufacturing, fill-finish, and cold-chain capacity to protect margins and supply reliability.
- Use the deal to identify adjacent cardiometabolic licensing or co-promotion opportunities.
The counter-case
The licensing deal may add strategic optionality rather than near-term value: lerodalcibep still faces regulatory, reimbursement, manufacturing-scale and launch-execution risks across a fragmented ex-US/ex-China territory set. The PCSK9 market is dominated by established products with entrenched payer contracts, physician familiarity and large commercial infrastructures, while newer lower-cost oral and injectable lipid-lowering alternatives could compress pricing. Without disclosed upfront payments, milestones, royalty rates, development responsibilities or launch timing, the financial attractiveness cannot be assessed.